Nucleic Acid Aptamers for Molecular Therapy of Epilepsy and Blood-Brain Barrier Damages

Duncan, 2006, Adult epilepsy, Lancet, 367, 1087, 10.1016/S0140-6736(06)68477-8

Brooks-Kayal, 2013, Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy, Epilepsia, 54, 44, 10.1111/epi.12298

Fisher, 2017, Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology, Epilepsia, 58, 522, 10.1111/epi.13670

Vezzani, 2017, Biomarkers of epileptogenesis: the focus on glia and cognitive dysfunctions, Neurochem. Res., 42, 2089, 10.1007/s11064-017-2271-3

Beamer, 2017, The ATP-gated P2X7 receptor as a target for the treatment of drug-resistant epilepsy, Front. Neurosci., 11, 21, 10.3389/fnins.2017.00021

Pitkänen, 2009, Molecular and cellular basis of epileptogenesis in symptomatic epilepsy, Epilepsy Behav., 14, 16, 10.1016/j.yebeh.2008.09.023

Pitkänen, 2011, Mechanisms of epileptogenesis and potential treatment targets, Lancet Neurol., 10, 173, 10.1016/S1474-4422(10)70310-0

Boison, 2013, Homeostatic control of brain function – new approaches to understand epileptogenesis, Front. Cell. Neurosci., 7, 109, 10.3389/fncel.2013.00109

Engel, 2005, Classification is not EZ, Epileptic Disord., 7, 317, 10.1684/j.1950-6945.2005.tb00133.x

Brodie, 2018, The 2017 ILAE classification of seizure types and the epilepsies: what do people with epilepsy and their caregivers need to know?, Epileptic Disord., 20, 77, 10.1684/epd.2018.0957

Surguchov, 2017, Pore-forming proteins as mediators of novel epigenetic mechanism of epilepsy, Front. Neurol., 8, 3, 10.3389/fneur.2017.00003

Rose, 2001, NMDA receptor-mediated Na+ signals in spines and dendrites, J. Neurosci., 21, 4207, 10.1523/JNEUROSCI.21-12-04207.2001

Pumain, 1985, Stimulus- and amino acid-induced calcium and potassium changes in rat neocortex, J. Neurophysiol., 53, 1, 10.1152/jn.1985.53.1.1

Rose, 2001, Exciting glial oscillations, Nat. Neurosci., 4, 773, 10.1038/90464

Ellender, 2014, Excitatory effects of parvalbumin-expressing interneurons maintain hippocampal epileptiform activity via synchronous afterdischarges, J. Neurosci., 34, 15208, 10.1523/JNEUROSCI.1747-14.2014

Villa, 2016, Potassium channels and human epileptic phenotypes: an updated overview, Front. Cell. Neurosci., 10, 81, 10.3389/fncel.2016.00081

Pitkänen, 2007, Epileptogenesis in experimental models, Epilepsia, 48, 13, 10.1111/j.1528-1167.2007.01063.x

Nissinen, 2000, A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat, Epilepsy Res., 38, 177, 10.1016/S0920-1211(99)00088-1

Rakhade, 2009, Epileptogenesis in the immature brain: emerging mechanisms, Nat. Rev. Neurol., 5, 380, 10.1038/nrneurol.2009.80

Lerche, 2001, Ion channels and epilepsy, Am. J. Med. Genet., 106, 146, 10.1002/ajmg.1582

Pal, 2010, Genetic evaluation and counseling for epilepsy, Nat. Rev. Neurol., 6, 445, 10.1038/nrneurol.2010.92

Wang, 2017, Epilepsy-associated genes, Seizure, 44, 11, 10.1016/j.seizure.2016.11.030

Wei, 2017, Ion channel genes and epilepsy: functional alteration, pathogenic potential, and mechanism of epilepsy, Neurosci. Bull., 33, 455, 10.1007/s12264-017-0134-1

Huber, 2001, Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier, Trends Neurosci., 24, 719, 10.1016/S0166-2236(00)02004-X

Ballabh, 2004, The blood-brain barrier: an overview: structure, regulation, and clinical implications, Neurobiol. Dis., 16, 1, 10.1016/j.nbd.2003.12.016

Cardoso, 2010, Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches, Brain Res. Brain Res. Rev., 64, 328, 10.1016/j.brainresrev.2010.05.003

Pardridge, 2007, Blood-brain barrier delivery, Drug Discov. Today, 12, 54, 10.1016/j.drudis.2006.10.013

Angelow, 2007, Claudins and paracellular transport: an update, Curr. Opin. Nephrol. Hypertens., 16, 459, 10.1097/MNH.0b013e32820ac97d

Schlosshauer, 2002, Comparative anatomy, physiology and in vitro models of the blood–brain and blood–retina barrier, Curr. Med. Chem.-Cent. Nerv. Syst. Agents, 2, 175, 10.2174/1568015023357978

Burnette, 1994, Comparison between passive transport of protein across excised nude mouse skin, J. Pharm. Sci., 75, 738, 10.1002/jps.2600750803

Pardridge, 2005, The blood-brain barrier: bottleneck in brain drug development, NeuroRx, 2, 3, 10.1602/neurorx.2.1.3

Abbott, 2010, Structure and function of the blood-brain barrier, Neurobiol. Dis., 37, 13, 10.1016/j.nbd.2009.07.030

Johansson, 1977, The pathophysiology of the blood-brain barrier dysfunction induced by severe hypercapnia and by epileptic brain activity, Acta Neuropathol., 38, 153, 10.1007/BF00688563

Petito, 1977, Ultrastructural characteristics of the brain and blood-brain barrier in experimental seizures, Brain Res., 127, 251, 10.1016/0006-8993(77)90539-X

Michalak, 2013, Spatio-temporally restricted blood-brain barrier disruption after intra-amygdala kainic acid-induced status epilepticus in mice, Epilepsy Res., 103, 167, 10.1016/j.eplepsyres.2012.10.006

van Vliet, 2007, Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy, Brain, 130, 521, 10.1093/brain/awl318

van Vliet, 2015, Blood-brain barrier dysfunction, seizures and epilepsy, Semin. Cell Dev. Biol., 38, 26, 10.1016/j.semcdb.2014.10.003

Friedman, 2009, Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy, Epilepsy Res., 85, 142, 10.1016/j.eplepsyres.2009.03.005

Marchi, 2007, Seizure-promoting effect of blood-brain barrier disruption, Epilepsia, 48, 732, 10.1111/j.1528-1167.2007.00988.x

Jobst, 2015, Consensus over individualism: validation of the ILAE definition for drug resistant epilepsy, Epilepsy Curr., 15, 172, 10.5698/1535-7511-15.4.172

Kwan, 2011, Drug-resistant epilepsy, N. Engl. J. Med., 365, 919, 10.1056/NEJMra1004418

Téllez-Zenteno, 2005, Sudden unexpected death in epilepsy: evidence-based analysis of incidence and risk factors, Epilepsy Res., 65, 101, 10.1016/j.eplepsyres.2005.05.004

Kwan, 2010, Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies, Epilepsia, 51, 1069, 10.1111/j.1528-1167.2009.02397.x

Brodie, 2012, Patterns of treatment response in newly diagnosed epilepsy, Neurology, 78, 1548, 10.1212/WNL.0b013e3182563b19

Meador, 2011, Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age, Brain, 134, 396, 10.1093/brain/awq352

Chung, 2011, New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapy, J. Epilepsy Res., 1, 35, 10.14581/jer.11008

Vogel, 1959, Moderne probleme der humangenetik, Med. Kinderheilkunde, 12, 52

Löscher, 2009, The clinical impact of pharmacogenetics on the treatment of epilepsy, Epilepsia, 50, 1, 10.1111/j.1528-1167.2008.01716.x

Lewis, 2005, Personalized drug therapy; the genome, the chip and the physician, Br. J. Clin. Pharmacol., 60, 1, 10.1111/j.1365-2125.2005.02457.x

Löscher, 2005, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases, Prog. Neurobiol., 76, 22, 10.1016/j.pneurobio.2005.04.006

Kwan, 2005, Potential role of drug transporters in the pathogenesis of medically intractable epilepsy, Epilepsia, 46, 224, 10.1111/j.0013-9580.2005.31904.x

Siddiqui, 2003, Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1, N. Engl. J. Med., 348, 1442, 10.1056/NEJMoa021986

Soranzo, 2004, Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene, Genome Res., 14, 1333, 10.1101/gr.1965304

Rogawski, 2004, The neurobiology of antiepileptic drugs, Nat. Rev. Neurosci., 5, 553, 10.1038/nrn1430

Bar-Klein, 2014, Losartan prevents acquired epilepsy via TGF-β signaling suppression, Ann. Neurol., 75, 864, 10.1002/ana.24147

Massagué, 2000, How cells read TGF-beta signals, Nat. Rev. Mol. Cell Biol., 1, 169, 10.1038/35043051

Shi, 2003, Mechanisms of TGF-beta signaling from cell membrane to the nucleus, Cell, 113, 685, 10.1016/S0092-8674(03)00432-X

Cacheaux, 2009, Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis, J. Neurosci., 29, 8927, 10.1523/JNEUROSCI.0430-09.2009

David, 2009, Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis?, J. Neurosci., 29, 10588, 10.1523/JNEUROSCI.2323-09.2009

Kaya, 2003, Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats, Life Sci., 73, 3235, 10.1016/j.lfs.2003.06.014

Kucuk, 2002, Effects of losartan on the blood-brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats, Life Sci., 71, 937, 10.1016/S0024-3205(02)01772-1

Librizzi, 2012, Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage, Ann. Neurol., 72, 82, 10.1002/ana.23567

Marchi, 2009, Antagonism of peripheral inflammation reduces the severity of status epilepticus, Neurobiol. Dis., 33, 171, 10.1016/j.nbd.2008.10.002

Fabene, 2008, A role for leukocyte-endothelial adhesion mechanisms in epilepsy, Nat. Med., 14, 1377, 10.1038/nm.1878

Da Pieve, 2010, Modification of thiol functionalized aptamers by conjugation of synthetic polymers, Bioconjug. Chem., 21, 169, 10.1021/bc900397s

Kang, 2009, Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers, Small, 5, 2519, 10.1002/smll.200900848

Sefah, 2010, Development of DNA aptamers using cell-SELEX, Nat. Protoc., 5, 1169, 10.1038/nprot.2010.66

Levy-Nissenbaum, 2008, Nanotechnology and aptamers: applications in drug delivery, Trends Biotechnol., 26, 442, 10.1016/j.tibtech.2008.04.006

Fang, 2010, Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach, Acc. Chem. Res., 43, 48, 10.1021/ar900101s

Zumrut, 2016, Ligand-guided selection of target-specific aptamers: a screening technology for identifying specific aptamers against cell-surface proteins, Nucleic Acid Ther., 26, 190, 10.1089/nat.2016.0611

Cui, 2004, Selection of stable RNA molecules that can regulate the channel-opening equilibrium of the membrane-bound gamma-aminobutyric acid receptor, Biochemistry, 43, 16442, 10.1021/bi048667b

Huang, 2012, RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB, Mol. Pharmacol., 82, 623, 10.1124/mol.112.078220

Scharfman, 2007, The neurobiology of epilepsy, Curr. Neurol. Neurosci. Rep., 7, 348, 10.1007/s11910-007-0053-z

Hanada, 2011, Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy, Epilepsia, 52, 1331, 10.1111/j.1528-1167.2011.03109.x

Huang, 2010, Potent and selective inhibition of the open-channel conformation of AMPA receptors by an RNA aptamer, Biochemistry, 49, 5790, 10.1021/bi100690k

Aarsland, 2009, Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial, Lancet Neurol., 8, 613, 10.1016/S1474-4422(09)70146-2

Calabresi, 2003, Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies, Neurobiol. Dis., 12, 82, 10.1016/S0969-9961(02)00016-5

Traynelis, 2010, Glutamate receptor ion channels: structure, regulation, and function, Pharmacol. Rev., 62, 405, 10.1124/pr.109.002451

Lee, 2014, RNA based antagonist of NMDA receptors, ACS Chem. Neurosci., 5, 559, 10.1021/cn500041k

Zakharov, 2007, Helical alpha-synuclein forms highly conductive ion channels, Biochemistry, 46, 14369, 10.1021/bi701275p

Lashuel, 2002, Neurodegenerative disease: amyloid pores from pathogenic mutations, Nature, 418, 291, 10.1038/418291a

Zheng, 2018, Novel DNA aptamers for Parkinson’s disease treatment inhibit α-synuclein aggregation and facilitate its degradation, Mol. Ther. Nucleic Acids, 11, 228, 10.1016/j.omtn.2018.02.011

Rempe, 2018, Matrix metalloproteinase-mediated blood-brain barrier dysfunction in epilepsy, J. Neurosci., 38, 4301, 10.1523/JNEUROSCI.2751-17.2018

Scarano, 2015, Design of a dual aptamer-based recognition strategy for human matrix metalloproteinase 9 protein by piezoelectric biosensors, Anal. Chim. Acta, 897, 1, 10.1016/j.aca.2015.07.009

Cheng, 2013, In vivo SELEX for Identification of brain-penetrating aptamers, Mol. Ther. Nucleic Acids, 2, e67, 10.1038/mtna.2012.59

Macdonald, 2017, Development of a bifunctional aptamer targeting the transferrin receptor and epithelial cell adhesion molecule (EpCAM) for the treatment of brain cancer metastases, ACS Chem. Neurosci., 8, 777, 10.1021/acschemneuro.6b00369

Zuberi, 1999, A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy, Brain, 122, 817, 10.1093/brain/122.5.817

Spampanato, 2004, A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction, J. Neurosci., 24, 10022, 10.1523/JNEUROSCI.2034-04.2004

Zamponi, 2010, Role of voltage-gated calcium channels in epilepsy, Pflugers Arch., 460, 395, 10.1007/s00424-009-0772-x

Vennekens, 2012, TRPs in the brain, Rev. Physiol. Biochem. Pharmacol., 163, 27

Raimondo, 2015, Ion dynamics during seizures, Front. Cell. Neurosci., 9, 419, 10.3389/fncel.2015.00419

N’Gouemo, 2013, Probing the role of the sodium/calcium exchanger in pentylenetetrazole-induced generalized seizures in rats, Brain Res. Bull., 90, 52, 10.1016/j.brainresbull.2012.09.007

Du, 2016, The influence of potassium concentration on epileptic seizures in a coupled neuronal model in the hippocampus, Cogn Neurodyn, 10, 405, 10.1007/s11571-016-9390-4

Bravo-Martínez, 2011, Analysis of plasma membrane Ca2+-ATPase gene expression during epileptogenesis employing single hippocampal CA1 neurons, Exp. Biol. Med. (Maywood), 236, 409, 10.1258/ebm.2011.010342

Becchetti, 2015, The role of nicotinic acetylcholine receptors in autosomal dominant nocturnal frontal lobe epilepsy, Front. Physiol., 6, 22, 10.3389/fphys.2015.00022

Liu, 2017, Seizure outcomes in patients with anti-NMDAR encephalitis: a follow-up study, Epilepsia, 58, 2104, 10.1111/epi.13929

Russo, 2012, New AMPA antagonists in epilepsy, Expert Opin. Investig. Drugs, 21, 1371, 10.1517/13543784.2012.705277

Crépel, 2015, Physiopathology of kainate receptors in epilepsy, Curr. Opin. Pharmacol., 20, 83, 10.1016/j.coph.2014.11.012

Funke, 2003, Calcium homeostasis and temporal lobe epilepsy, Arq. Neuropsiquiatr., 61, 8

Engelborghs, 2000, Pathophysiology of epilepsy, Acta Neurol. Belg., 100, 201

Binder, 2012, Aquaporin-4 and epilepsy, Glia, 60, 1203, 10.1002/glia.22317

Huang, 2007, RNA aptamers selected against the GluR2 glutamate receptor channel, Biochemistry, 46, 12648, 10.1021/bi701036p

Huang, 2017, Chemically modified, α-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) receptor RNA aptamers designed for in vivo use, ACS Chem. Neurosci., 8, 2437, 10.1021/acschemneuro.7b00211